SHARE: +/-: 0.00 SEK / Bid: 14.75 SEK / Ask: 15.50 SEK / Price: 15.50 SEK / High: 15.80 SEK / Low: 14.80 SEK / Quantity: 3 717 / Turnover: 56 878 SEK / 2019-12-13 16:28 (CET)
 

News

Investigation of gadolinium may lead to increased for MRI contrast agents with manganese

Basically all approved contrast agents for MRI are based on the basic element gadolinium (Gd). The use of the Gd, which is foreign to the body, in some contrast agents been related to serious adverse reactions in groups of patients with impaired renal function. More recently it has also been documented…
Read more

Invitation to presentation of Spago Nanomedical AB’s year-end report for 2016

Spago Nanomedical AB publishes its year-end report for 2016 on February 14.
Read more

Promising results of treatment with internal radionuclide therapy

A paper in New England Journal of Medicine report on promising results from a phase 3 study of the radioactive substance lutetium-177 (Lu177) in patients with advanced cancer in the mid-gut. The study present results from 229 patients with metastatic neuroendocrine tumors treated with standard of care by means of octreotide, or Lu177 in combination with octreotide. Following 20 months the proportion of patients that were…
Read more

Danish study suggests need for improved diagnostics for breast cancer

A paper that was recently published in Annals of Internal Medicine reports a high risk of missing the most aggressive tumors in screening by mammography. The study summarize results from mammography screening of a large number of women in Danmark from 1980 to 2010 and concludes a high rate of overdiagnosis by means of X-ray mammography. The results implicate the need…
Read more

Swedish nanotechnology a new weapon in the fight against cancer

Article about Spago in "Innovation mot Cancer" (in Swedish), see here.
Read more

Production of SpagoPix ongoing

Following successful initial production of a large-scale test batch, a production campaign in clean-room with the aim of producing enough SpagoPix-material to supply the planned preclinical program is ongoing.
Read more

Pilot study suggest role of MRI in primary screening for prostate cancer

In a pilot study recently published in The Journal of Urology researchers at the University of Toronto have investigated the utility of MRI for early screening of prostate cancer in the general population. A group of men 50 to 75 years of age and without previous signs of prostate cancer…
Read more

Andreas Gram appointed Production Manager

As a step towards the internal scale-up of the SpagoPix-production for regulatory studies, Andreas Gram has been appointed Production Manager. Andreas has a solid background in contrast media development and production from earlier positions, e.g. at GE Healthcare, and has worked in Spago Nanomedical since mid-2015 with preparations of premises…
Read more

Spago Nanomedical launches new website and visual identity

Spago Nanomedical today launches an improved and more visitor-friendly website. Information about the company is now available in both Swedish and English. In connection with the updating of the website, Spago Nanomedical has also created a new visual identity that includes a new logo . The work has been done…
Read more

Mats Hansen om Spago Nanomedicals verksamhet

Följ länken för presentation av Mats Hansen vid Aktietorgets investerarlunch i Stockholm den 10e maj 2016. http://www.svd.se/spago-nanomedical-intensifierar-jakten-pa-tumorer  
Read more